Bladder Cancer - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Bladder Cancer > What Your Doctor is Reading About Bladder Cancer > General Interest Articles

General Interest Articles

1. Bladder and upper tract urothelial cancer.

Author: Konety BR; Joyce GF; Wise M;
Institution: Department of Urology, University of California-San Francisco, San Francisco, CA 94143-1695, USA. bkonety@urology.ucsf.edu
Journal: J Urol. 2007 May;177(5):1636-45.
Abstract URL: Click here to view abstract

2. Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments.

Author: Sanderson KM; Roupret M;
Institution: Urologic Oncology, Department of Urology, Keck School of Medicine, University of Southern California, USC/Norris Cancer Center, Los Angeles, CA, USA.
Journal: BJU Int. 2007 Apr 8;.
Abstract URL: Click here to view abstract

3. Superficial bladder cancer: part 2. Management.

Author: Josephson D; Pasin E; Stein JP;
Institution: University of Southern California, Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90089-9178, USA. david.josephson@usc.edu
Journal: Expert Rev Anticancer Ther. 2007 Apr;7(4):567-81.
Abstract URL: Click here to view abstract

4. Bladder cancer.

Author: Clark PE;
Institution: Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2765, USA. peter.clark@vanderbilt.edu
Journal: Curr Opin Oncol. 2007 May;19(3):241-7.
Abstract URL: Click here to view abstract

5. Multimodality bladder preservation therapy for muscle-invasive bladder tumors.

Author: Fernando SA; Sandler HM;
Institution: Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Journal: Semin Oncol. 2007 Apr;34(2):129-34.
Abstract URL: Click here to view abstract

6. Urinary diversion: options, patient selection, and outcomes.

Author: Parekh DJ; Donat SM;
Institution: Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Journal: Semin Oncol. 2007 Apr;34(2):98-109.
Abstract URL: Click here to view abstract

7. Advances in the management of superficial bladder cancer.

Author: O'Donnell MA;
Institution: Department of Urology, University of Iowa, Iowa City, IA, USA. michael-odonnell@uiowa.edu
Journal: Semin Oncol. 2007 Apr;34(2):85-97.
Abstract URL: Click here to view abstract

8. Behavior of urothelial carcinoma with respect to anatomical location.

Author: Catto JW; Yates DR; Rehman I; Azzouzi AR; Patterson J; Sibony M; Cussenot O; Hamdy FC;
Institution: Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom. J.Catto@sheffield.ac.uk
Journal: J Urol. 2007 May;177(5):1715-20.
Abstract URL: Click here to view abstract

9. The management of superficial bladder cancer.

Author: Dalbagni G;
Institution: Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. dalbagng@mskcc.org
Journal: Nat Clin Pract Urol. 2007 May;4(5):254-60.
Abstract URL: Click here to view abstract

10. Chronic inflammation and bladder cancer.

Author: Michaud DS;
Institution: Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.
Journal: Urol Oncol. 2007 May-Jun;25(3):260-8.
Abstract URL: Click here to view abstract

11. Benign prostatic hyperplasia and subsequent risk of bladder cancer.

Author: Kang D; Chokkalingam AP; Gridley G; Nyren O; Johansson JE; Adami HO; Silverman D; Hsing AW;
Institution: [1] 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA [2] 2College of Medicine, Seoul National University, Seoul, Korea.
Journal: Br J Cancer. 2007 May 7;96(9):1475-9. Epub 2007 May 1.
Abstract URL: Click here to view abstract

12. Hospital Volume and Late Survival After Cancer Surgery.

Author: Birkmeyer JD; Sun Y; Wong SL; Stukel TA;
Institution: From the *Michigan Surgical Collaborative for Outcomes Research and Evaluation, Department of Surgery, University of Michigan, Ann Arbor, MI; and daggerInstitute for the Clinical Evaluative Sciences and Department of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Journal: Ann Surg. 2007 May;245(5):777-783.
Abstract URL: Click here to view abstract

13. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.

Author: Denzinger S; Burger M; Walter B; Knuechel R; Roessler W; Wieland WF; Filbeck T;
Institution: Department of Urology, University of Regensburg, Regensburg, Germany. stefandenzinger@hotmail.com
Journal: Urology. 2007 Apr;69(4):675-9.
Abstract URL: Click here to view abstract

14. Lymphatic invasion is a prognostic factor for bladder cancer treated with radical cystectomy.

Author: Horikawa Y; Kumazawa T; Narita S; Inoue T; Yuasa T; Matsuura S; Nanjo H; Satoh S; Tsuchiya N; Habuchi T;
Institution: Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan, thabuchi@doc.med.akita-u.ac.jp.
Journal: Int J Clin Oncol. 2007 Apr;12(2):131-6. Epub 2007 Apr 27.
Abstract URL: Click here to view abstract

15. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives.

Author: Yossepowitch O; Herr HW; Donat SM;
Institution: Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Journal: J Urol. 2007 Apr;177(4):1277-82; discussion 1282.
Abstract URL: Click here to view abstract

16. Molecular therapeutic targets for bladder cancer.

Author: Zacharakis E; Monem M; Joseph JV; Patel HR;
Institution
Journal: Expert Rev Anticancer Ther. 2007 Dec;7(12):1691-3.

17. Holmium laser treatment for low grade, low stage, noninvasive bladder cancer with local anesthesia and early instillation of mitomycin C.

Author: Soler-Martinez J; Vozmediano-Chicharro R; Morales-Jimenez P; Hernandez-Alcaraz D; Vivas-Vargas E; Santos Garcia-Vaquero I; Baena-Gonzalez V;
Institution: Servicio de Urologia, Hospital Regional Universitario Carlos Haya, Malaga, Spain. jorge_soler_martinez@yahoo.es
Journal: J Urol. 2007 Dec;178(6):2337-9. Epub 2007 Oct 22.
Abstract URL: Click here to view abstract

18. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer.

Author: Chen CH; Shun CT; Huang KH; Huang CY; Tsai YC; Yu HJ; Pu YS;
Institution: Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
Journal: BJU Int. 2007 Aug;100(2):281-6; discussion 286. Epub 2007 Apr 5.
Abstract URL: Click here to view abstract

19. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI).

Author: Gilbert SM; Wood DP; Dunn RL; Weizer AZ; Lee CT; Montie JE; Wei JT;
Institution: Department of Urology, Divisions of Health Services Research and Urologic Oncology, University of Michigan, Ann Arbor, Michigan.
Journal: Cancer. 2007 Mar 15;109(9):1756-1762.
Abstract URL: Click here to view abstract

20. Lack of progress in early diagnosis of bladder cancer.

Author: Araki M; Nieder AM; Manoharan M; Yang Y; Soloway MS;
Institution: Department of Urology, University of Miami Miller School of Medicine, Miami Beach, Florida 33140, USA.
Journal: Urology. 2007 Feb;69(2):270-4.
Abstract URL: Click here to view abstract

21. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.

Author: Shariat SF; Ashfaq R; Karakiewicz PI; Saeedi O; Sagalowsky AI; Lotan Y;
Institution: Department of Urology, University of Texas Southwestern Medical Center at Dallas, Texas 75390-9110, USA. Shahrokh.Shariat@UTSouthwestern.edu
Journal: Cancer. 2007 Mar 15;109(6):1106-13.
Abstract URL: Click here to view abstract

22. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha.

Author: Esuvaranathan K; Chiong E; Thamboo TP; Chan YH; Kamaraj R; Mahendran R; Teh M;
Institution: Department of Surgery, National University of Singapore, Singapore. suresuva@nus.edu.sg
Journal: Cancer. 2007 Mar 15;109(6):1097-105.
Abstract URL: Click here to view abstract

23. Survivin: A promising tumor biomarker.

Author: Duffy MJ; O'donovan N; Brennan DJ; Gallagher WM; Ryan BM;
Institution: Department of Pathology and Laboratory Medicine, St. Vincent's University Hospital, Dublin 4, Ireland; UCD School of Medicine and Medical Science, University College Dublin, Dublin 4, Ireland.
Journal: Cancer Lett. 2007 Apr 28;249(1):49-60. Epub 2007 Feb 1.
Abstract URL: Click here to view abstract

24. A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke.

Author: Alberg AJ; Kouzis A; Genkinger JM; Gallicchio L; Burke AE; Hoffman SC; Diener-West M; Helzlsouer KJ; Comstock GW;
Institution: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. alberg@musc.edu
Journal: Am J Epidemiol. 2007 Mar 15;165(6):660-6. Epub 2007 Jan 4.
Abstract URL: Click here to view abstract

25. Where are we with the treatment of metastatic bladder cancer?

Author: Papatsoris AG; Kachrilas S; Gekas A;
Institution: Agios Andreas Regional Hospital, Department of Urology, Patras, Greece. agpapatsoris@yahoo.gr
Journal: Expert Opin Investig Drugs. 2007 Sep;16(9):1311-4.
Abstract URL: Click here to view abstract

26. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer.

Author: Weizer AZ; Joshi D; Daignault S; Kinnaman M; Hussain M; Montie JE; Zhang Y; Lee CT;
Institution: Department of Urology, University of Michigan, Ann Arbor, Michigan 48109, USA.
Journal: J Urol. 2007 Apr;177(4):1287-93.
Abstract URL: Click here to view abstract

27. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.

Author: Raj GV; Herr H; Serio AM; Donat SM; Bochner BH; Vickers AJ; Dalbagni G;
Institution: Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Journal: J Urol. 2007 Apr;177(4):1283-6; discussion 1286.
Abstract URL: Click here to view abstract

28. Angiosarcoma of bladder: long-term survival after multimodal therapy.

Author: Pazona JF; Gupta R; Wysock J; Schaeffer AJ; Smith ND;
Institution: Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.
Journal: Urology. 2007 Mar;69(3):575.e9-10.
Abstract URL: Click here to view abstract

29. Does body mass index affect outcome after reconstruction of orthotopic neobladder?

Author: Reyes MA; Nieder AM; Kava BR; Soloway MS; Manoharan M;
Institution: Department of Urology, University of Miami Miller School of Medicine, Miami, Florida 33101, USA.
Journal: Urology. 2007 Mar;69(3):475-8.
Abstract URL: Click here to view abstract

30. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.

Author: Sharma P; Shen Y; Wen S; Yamada S; Jungbluth AA; Gnjatic S; Bajorin DF; Reuter VE; Herr H; Old LJ; Sato E;
Institution: Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. padsharma@mdanderson.org
Journal: Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72. Epub 2007 Feb 27.
Abstract URL: Click here to view abstract

31. Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.

Author: Higano CS; Tangen CM; Sakr WA; Faulkner J; Rivkin SE; Meyers FJ; Hussain M; Baker LH; Russell KJ; Crawford ED;
Institution: Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA.
Journal: Cancer. 2008 May 15;112(10):2181-7.
Abstract URL: Click here to view abstract

32. Review of the M.D. Anderson experience in the treatment of bladder sarcoma.

Author: Spiess PE; Kassouf W; Steinberg JR; Tuziak T; Hernandez M; Tibbs RF; Czerniak B; Kamat AM; Dinney CP; Grossman HB;
Institution: Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA.
Journal: Urol Oncol. 2007 Jan-Feb;25(1):38-45.
Abstract URL: Click here to view abstract